These findings bear implications for the follow‐up of patients with NRAS‐mutant primary tumors, for the prevention of pulmonary metastasis in such patients, and for future trial design in patients with solid tumors with high NRAS mutation frequencies, such as melanoma. The gene discussed is NRAS; the disease is melanoma.